Kalaris Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Kalaris Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. ...
The story matters when it changes Kalaris Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Kalaris Therapeutics, Inc. Common Stock (KLRS) SEC Filings
Investors are testing whether Kalaris Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest KLRS filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Kalaris Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →